ClinicalTrials.gg
CompletedNCT01471782Updated Feb 8, 2017Results posted

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

A Phase 1/2 interventional study of Blinatumomab in Acute Lymphoblastic Leukemia, sponsored by Amgen Research (Munich) GmbH. Completed at 30 sites in 7 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2017-02-08.

Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
93
Allocation
Not applicable
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
26th of 61
93 · median 67
Started
2012
the only one that year
Phase 1/2
8 of 61
2 open now
Registered
4th of 61
by date
Lead sponsor
5 of 61
Amgen Research (Munich) GmbH

Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 26th largest by enrollment, is the only one that started in 2012, is one of 8 in phase 1/2, and was the 4th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The purpose of this study is to determine the dose of the bispecific T cell engager blinatumomab (MT103) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and to assess whether this dose of blinatumomab is effective.

Read the detailed description

Childhood acute lymphoblastic leukemia (ALL) is a type of cancer of the blood and bone marrow in which the bone marrow makes too many abnormal immature lymphocytes.

Blinatumomab is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T cell activation and a cytotoxic T cell response against cluster of differentiation (CD)19 expressing cells.

The purpose of this study is to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of escalating doses of blinatumomab in pediatric and adolescent patients with relapsed/refractory B-precursor ALL, to select a dose and to investigate the efficacy and safety of that dose of blinatumomab in the above-mentioned patient population.

The phase 1 part of the study included the evaluation of four dose levels of blinatumomab with comprehensive PK/PD assessments and was separated in 2 parts:

  • Phase 1 dose evaluation/escalation part to define the recommended phase 2 dose of blinatumomab in patients aged 2 to 17 years
  • Phase 1 PK expansion part in patients aged \< 18 years to further assess PK/PD at the recommended phase 2 dose. In this part additional participants were enrolled to ensure that 6 patients in each of the 2 older age groups (2-6 and 7-17 years) were analyzed for PK before recruitment of infants \< 2 years of age began.

In the phase 2 extension cohort (efficacy phase) of the study, eligible participants less than 18 years were enrolled according to a two-stage design and received blinatumomab at the recommended dose level (5/15 μg/m²/day).

The study consisted of a screening period, a treatment period, and an End of Core Study visit 30 days after last dose of study medication. A treatment cycle consisted of a continuous intravenous (cIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks. Participants who achieved complete remission (CR) within 2 cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab. Instead of consolidation cycles with blinatumomab, participants could be withdrawn from blinatumomab treatment to receive chemotherapy or allogeneic HSCT as early as the first cycle, at the discretion of the investigator.

After the last treatment cycle and End of Core Study visit, all participants were followed for efficacy and survival for up to 24 months after treatment start. Participants who suffered a hematological relapse of B-precursor ALL during their follow-up period (at least 3 months after completion of treatment) had the possibility for retreatment with blinatumomab.

03

Conditions studied

  • Acute Lymphoblastic Leukemia

Keywords

  • ALL
  • relapsed, refractory B-precursor ALL
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia
  • Neoplasms by Histologic Type
  • Neoplasms
  • Lymphoproliferative Disorders
  • Lymphatic Diseases
  • Immunoproliferative Disorders
  • Antibodies, Bispecific
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Morphologic evidence of B-precursor ALL with > 25% blasts in bone marrow (M3) at study enrolment
  • Age less than 18 years at enrollment
  • disease:

    • Second or later bone marrow relapse,
    • Any marrow relapse after hematopoietic stem cell transplantation (HSCT), or
    • Refractory to other treatments: Patients in first relapse must have failed to achieve a CR following full standard reinduction chemotherapy regimen of at least 4 weeks duration. Patients who have not achieved a first remission must have failed a full standard induction regimen
  • performance status more than or equal to 50% for patients more than or equal to 16 years and Lansky Performance Status (LPS) of more than or equal to 50% for patients less than 16 years
  • Organ function requirements: All patients must have adequate renal and liver functions

Exclusion criteria

Exclusion Criteria:

  • Active acute or extensive chronic (GvHD)
  • agents to prevent or treat GvHD within 2 weeks prior to blinatumomab treatment
  • Evidence for current central nervous system (CNS) involvement by ALL (CNS 2, CNS 3) or testicular involvement by ALL
  • History of relevant CNS pathology or current relevant CNS pathology
  • History of disease with potential CNS involvement or current autoimmune disease
  • Any within 3 months prior to blinatumomab treatment
  • Cancer chemotherapy within 2 weeks prior to blinatumomab treatment (except for intrathecal chemotherapy and/or low dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, )
  • Chemotherapy related toxicities that haven't resolved to less than or equal to Grade 2
  • Radiotherapy within 2 weeks prior to blinatumomab treatment
  • Immunotherapy (e.g. rituximab, alemtuzumab) within 6 weeks prior to blinatumomab treatment
  • Any product within 4 weeks prior to study entry
  • Previous treatment with blinatumomab
  • Active severe infection, any other concurrent disease or medical condition that could be exacerbated by the treatment or would seriously complicate compliance with the protocol
  • Known infection with (HIV) or chronic infection with virus (HbsAg positive) or virus (anti-HCV positive)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Blinatumomab

    Blinatumomab was administered as a continuous intravenous (cIV) infusion at a constant daily flow rate over 4 weeks followed by a treatment-free interval of 2 weeks. Doses ranged between 5 and 30 µg/m²/day. Each participant received up to five cycles of treatment.

    Biological: Blinatumomab

Interventions

  • BiologicalBlinatumomab

    Administered by continuous intravenous infusion

    Also known as: MT103, AMG103, BLINCYTO®

06

What researchers measure

Primary outcomes

  1. Phase I: Number of Participants With Dose-limiting Toxicities (DLTs)

    The maximum tolerated dose (MTD) was defined as one or fewer out of 6 participants experiencing a dose limiting toxicity (DLT) or the maximum administered dose (MAD). A dose limiting toxicity is any Grade ≥ 3 adverse event related to study drug, Grade 3 fatigue, headache, insomnia, fever, hypotension or infection were not considered dose limiting toxicities. Laboratory parameters of Grade ≥ 3 but not considered as clinically relevant and/or responding to routine medical management, thrombocytopenia, leukopenia (including neutropenia and lymphopenia), and anemia were not considered dose limiting toxicities.

    Time frame: Cycle 1, 28 days

  2. Percentage of Participants With Complete Remission in the First Two Cycles

    Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central laboratory. Complete remission (CR) was defined as * M1 bone marrow (bone marrow blasts \< 5%) * No evidence of circulating blasts or extra-medullary disease Complete remission includes participants with incomplete recovery of peripheral blood counts.

    Time frame: Cycles 1 and 2 (12 weeks)

Secondary outcomes

  1. Number of Participants With Adverse Events

    The severity (or intensity) of adverse events (AEs) was assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), v4.03 and according to the following: Grade 1 - Mild adverse event; Grade 2 - Moderate adverse event; Grade 3 - Severe and undesirable adverse event; Grade 4 - Life-threatening or disabling adverse event; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab.

    Time frame: From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle, median treatment duration was 28 days

  2. Steady State Concentration of Blinatumomab

    Blinatumomab serum concentrations were quantified in all patients during the first 2 treatment cycles in the phase 1 part of the study only. Blinatumomab concentrations were quantified using a validated bioassay, the lower limit of quantification was 50 pg/mL. Steady state serum concentration (Css) was presumed on day 1, approximately 5 half-lives after the start of the IV infusion. The steady state serum concentration reported is the mean of the observed concentrations collected after during cycles 1 and 2.

    Time frame: Cycles 1 and 2 during the IV infusion on day 3 (at least 48 hours after start of infusion) and days 8, 15 and 22 (steady state) and day 29 at End of Infusion (EoI) and 2, 4, and 8 hours after EoI for ages ≥ 2 years.

  3. Time to Hematological Relapse (Duration of Response)

    Time to hematological relapse was measured only for participants in remission and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their date of death. Hematological relapse is defined as the proportion of blasts in bone marrow \> 25% following documented remission, or extramedullary relapse. Time to hematological relapse was analyzed by Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.

    Time frame: Up to the data cut-off date of 12 January 2015; median observation time was 23.5 months for phase 1 and 11.5 months for phase 2.

  4. Overall Survival

    Overall survival (OS) was measured for all participants from the first treatment of blinatumomab until death due to any cause or the date of the last follow-up. Participants who did not die were censored on the last documented visit date or the date of the last contact when the patient was last known to have been alive. For patients who withdrew their informed consent only information until the date of withdrawal was analyzed. Overall survival was estimated using Kaplan-Meier methods. The median follow-up time with respect to overall survival was calculated by the reverse Kaplan-Meier method.

    Time frame: Up to the data cut-off date of 12 January 2015; median observation time was 23.5 months for phase 1 and 11.6 months for phase 2.

  5. Relapse-free Survival

    Relapse-free survival (RFS) was assessed for participants who achieved a complete remission during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse free survival was estimated using Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan-Meier method.

    Time frame: Up to the data cut-off date of 12 January 2015; median observation time was 23.5 months for phase 1 and 11.5 months for phase 2.

  6. Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant During Blinatumomab Induced Remission

    The percentage of participants who received allogeneic hematopoietic stem cell transplantation (HSCT) while in remission due to treatment with blinatumomab during the first two cycles, and received no further anti-leukemic medication before HSCT.

    Time frame: Up to the data cut-off date of 12 January 2015; Maximum duration on study was 24 months in phase 1 and 15 months for phase 2.

  7. Number of Participants Who Developed Anti-blinatumomab Antibodies

    Antibodies to blinatumomab were detected using an electrochemiluminescence (ECL)-based assay.

    Time frame: Predose up until 30 days after last dose of study medication; median treatment duration was 28 days.

  8. Serum Cytokine Peak Levels

    The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor-alpha (TNF-α) and interferon gamma (IFN-ɣ) using cytometric bead assays. The limit of detection of the assay (LOD) was 20 pg/mL and the lower limit of quantification (LLOQ) was 125 pg/mL. Data below LOD were set to 10 pg/mL while data \< LOQ and \> LOD were reported as measured.

    Time frame: Cycle 1 and 2 day 1 (prior to infusion, 2 and 6 hours after infusion start), day 2 and day 3.

07

Results

Posted Feb 8, 2017

Participant flow

The study was conducted in 26 centers in Germany, France, Italy, the Netherlands, the United Kingdom, and the United States of America. Results are reported for the primary analysis with a data cut-off date of 12 January 2015.

Participant flow — Overall Study
MilestonePhase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/DayPhase 1: Blinatumomab 15/30 µg/m²/DayPhase 1: Blinatumomab 5/15 µg/m²/DayPhase 2: Blinatumomab 5/15 µg/m²/Day
Started57562644
Completed010103
Not completed56552641
Withdrew: Hematopoietic stem cell transplantation221053
Withdrew: Lack of efficacy1211518
Withdrew: Adverse event112231
Withdrew: Other001165
Withdrew: Change of chemotherapy110014
Withdrew: Disease relapse000121
Withdrew: Physician decision000038
Withdrew: Withdrawal by parent/guardian000010
Withdrew: Death000001

Outcome measures

PrimaryPhase I: Number of Participants With Dose-limiting Toxicities (DLTs)

The maximum tolerated dose (MTD) was defined as one or fewer out of 6 participants experiencing a dose limiting toxicity (DLT) or the maximum administered dose (MAD). A dose limiting toxicity is any Grade ≥ 3 adverse event related to study drug, Grade 3 fatigue, headache, insomnia, fever, hypotension or infection were not considered dose limiting toxicities. Laboratory parameters of Grade ≥ 3 but not considered as clinically relevant and/or responding to routine medical management, thrombocytopenia, leukopenia (including neutropenia and lymphopenia), and anemia were not considered dose limiting toxicities.

Time frame:
Cycle 1, 28 days
Reported as:
Number · participants
Phase I: Number of Participants With Dose-limiting Toxicities (DLTs)
participantsPhase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/DayPhase 1: Blinatumomab 15/30 µg/m²/Day
Phase I: Number of Participants With Dose-limiting Toxicities (DLTs)0121
PrimaryPercentage of Participants With Complete Remission in the First Two Cycles

Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central laboratory. Complete remission (CR) was defined as * M1 bone marrow (bone marrow blasts \< 5%) * No evidence of circulating blasts or extra-medullary disease Complete remission includes participants with incomplete recovery of peripheral blood counts.

Time frame:
Cycles 1 and 2 (12 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission in the First Two Cycles
percentage of participantsPhase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/DayPhase 1: Blinatumomab 15/30 µg/m²/DayPhase 1: Blinatumomab 5/15 µg/m²/DayPhase 2: Blinatumomab 5/15 µg/m²/DayPhase 1+2: Blinatumomab 5/15 µg/m²/Day
Percentage of Participants With Complete Remission in the First Two Cycles20.0 (0.5 to 71.6)42.9 (9.9 to 81.6)20.0 (0.5 to 71.6)33.3 (4.3 to 77.7)50.0 (29.9 to 70.1)31.8 (18.6 to 47.6)38.6 (27.2 to 51.0)
SecondaryNumber of Participants With Adverse Events

The severity (or intensity) of adverse events (AEs) was assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), v4.03 and according to the following: Grade 1 - Mild adverse event; Grade 2 - Moderate adverse event; Grade 3 - Severe and undesirable adverse event; Grade 4 - Life-threatening or disabling adverse event; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab.

Time frame:
From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle, median treatment duration was 28 days
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsPhase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1+2: Blinatumomab 5/15 µg/m²/DayPhase 1: Blinatumomab 15/30 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/Day
Any adverse event (AE)577065
Adverse event of at least CTC grade 3476165
Serious adverse event (SAEs)443943
SAE of at least grade 3432843
AE leading to interruption of study drug001022
AE leading to discontinuation of study drug11422
Adverse event leading to death01831
Treatment-related adverse event (TRAE)565955
TRAE of at least CTC grade 3453845
Treatment-related serious adverse event321512
TRAE leading to discontinuation of study drug11212
TRAE leading to death00010
SecondarySteady State Concentration of Blinatumomab

Blinatumomab serum concentrations were quantified in all patients during the first 2 treatment cycles in the phase 1 part of the study only. Blinatumomab concentrations were quantified using a validated bioassay, the lower limit of quantification was 50 pg/mL. Steady state serum concentration (Css) was presumed on day 1, approximately 5 half-lives after the start of the IV infusion. The steady state serum concentration reported is the mean of the observed concentrations collected after during cycles 1 and 2.

Time frame:
Cycles 1 and 2 during the IV infusion on day 3 (at least 48 hours after start of infusion) and days 8, 15 and 22 (steady state) and day 29 at End of Infusion (EoI) and 2, 4, and 8 hours after EoI for ages ≥ 2 years.
Reported as:
Mean · pg/mL
Steady State Concentration of Blinatumomab
pg/mLPhase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/Day
Cycle 1 (N = 27, 34, 7)162 ± 179533 ± 3921520 ± 1020
Cycle 2 (N = 3, 13, 5)456 ± 288866 ± 6551150 ± 701
SecondaryTime to Hematological Relapse (Duration of Response)

Time to hematological relapse was measured only for participants in remission and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their date of death. Hematological relapse is defined as the proportion of blasts in bone marrow \> 25% following documented remission, or extramedullary relapse. Time to hematological relapse was analyzed by Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.

Time frame:
Up to the data cut-off date of 12 January 2015; median observation time was 23.5 months for phase 1 and 11.5 months for phase 2.
Reported as:
Median · months
Time to Hematological Relapse (Duration of Response)
monthsPhase 1: BlinatumomabPhase 2: Blinatumomab 5/15 µg/m²/DayPhase 1+2: Blinatumomab 5/15 µg/m²/Day
Time to Hematological Relapse (Duration of Response)10.3 (3.9 to 16.4)3.4 (1.7 to NA)5.2 (2.3 to 16.4)
SecondaryOverall Survival

Overall survival (OS) was measured for all participants from the first treatment of blinatumomab until death due to any cause or the date of the last follow-up. Participants who did not die were censored on the last documented visit date or the date of the last contact when the patient was last known to have been alive. For patients who withdrew their informed consent only information until the date of withdrawal was analyzed. Overall survival was estimated using Kaplan-Meier methods. The median follow-up time with respect to overall survival was calculated by the reverse Kaplan-Meier method.

Time frame:
Up to the data cut-off date of 12 January 2015; median observation time was 23.5 months for phase 1 and 11.6 months for phase 2.
Reported as:
Median · months
Overall Survival
monthsPhase 1: BlinatumomabPhase 2: Blinatumomab 5/15 µg/m²/DayPhase 1+2: Blinatumomab 5/15 µg/m²/Day
Overall Survival6.5 (3.6 to 10.6)8.2 (4.0 to 14.6)7.5 (4.0 to 11.8)
SecondaryRelapse-free Survival

Relapse-free survival (RFS) was assessed for participants who achieved a complete remission during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse free survival was estimated using Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan-Meier method.

Time frame:
Up to the data cut-off date of 12 January 2015; median observation time was 23.5 months for phase 1 and 11.5 months for phase 2.
Reported as:
Median · months
Relapse-free Survival
monthsPhase 1: BlinatumomabPhase 2: Blinatumomab 5/15 µg/m²/DayPhase 1+2: Blinatumomab 5/15 µg/m²/Day
Relapse-free Survival7.9 (3.0 to 12.4)3.4 (1.7 to 13.9)4.4 (2.3 to 12.1)
SecondaryPercentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant During Blinatumomab Induced Remission

The percentage of participants who received allogeneic hematopoietic stem cell transplantation (HSCT) while in remission due to treatment with blinatumomab during the first two cycles, and received no further anti-leukemic medication before HSCT.

Time frame:
Up to the data cut-off date of 12 January 2015; Maximum duration on study was 24 months in phase 1 and 15 months for phase 2.
Reported as:
Number · percentage of participants
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant During Blinatumomab Induced Remission
percentage of participantsPhase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/DayPhase 1: Blinatumomab 15/30 µg/m²/DayPhase 1: Blinatumomab 5/15 µg/m²/DayPhase 2: Blinatumomab 5/15 µg/m²/DayPhase 1+2: Blinatumomab 5/15 µg/m²/Day
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant During Blinatumomab Induced Remission20.0 (0.5 to 71.6)28.6 (3.7 to 71.0)20.0 (0.5 to 71.6)16.7 (0.4 to 64.1)30.8 (14.3 to 51.8)11.4 (3.8 to 24.6)18.6 (10.3 to 29.7)
SecondaryNumber of Participants Who Developed Anti-blinatumomab Antibodies

Antibodies to blinatumomab were detected using an electrochemiluminescence (ECL)-based assay.

Time frame:
Predose up until 30 days after last dose of study medication; median treatment duration was 28 days.
Reported as:
Number · participants
Number of Participants Who Developed Anti-blinatumomab Antibodies
participantsPhase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/DayPhase 1: Blinatumomab 15/30 µg/m²/DayPhase 1: Blinatumomab 5/15 µg/m²/DayPhase 2: Blinatumomab 5/15 µg/m²/Day
Number of Participants Who Developed Anti-blinatumomab Antibodies000000
SecondarySerum Cytokine Peak Levels

The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor-alpha (TNF-α) and interferon gamma (IFN-ɣ) using cytometric bead assays. The limit of detection of the assay (LOD) was 20 pg/mL and the lower limit of quantification (LLOQ) was 125 pg/mL. Data below LOD were set to 10 pg/mL while data \< LOQ and \> LOD were reported as measured.

Time frame:
Cycle 1 and 2 day 1 (prior to infusion, 2 and 6 hours after infusion start), day 2 and day 3.
Reported as:
Mean · pg/mL
Serum Cytokine Peak Levels
pg/mLPhase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/Day
IL-6: Cycle 1 Week 1 (N=31, 13, 5)4970 ± 170001780 ± 262023400 ± 24100
IL-6: Cycle 2 Week 1 (N=4, 14, 5)526 ± 844892 ± 237040.4 ± 68.0
IL-10: Cycle 1 Week 1 (N=31, 13, 5)562 ± 7101400 ± 20303170 ± 1720
IL-10: Cycle 2 Week 1 (N=4, 14, 5)519 ± 497432 ± 692277 ± 308
IFN-ɣ: Cycle 1 Week 1 (N=31, 13, 5)207 ± 516539 ± 12402260 ± 1540
IFN-ɣ: Cycle 2 Week 1 (N=4, 14, 5)51.8 ± 65.647.6 ± 51.522.8 ± 28.6
IL-2: Cycle 1 Week 1 (N=31, 13, 5)22.7 ± 2393.9 ± 150900 ± 1390
IL-2: Cycle 2 Week 1 (N=4, 14, 5)10.0 ± 0.0014.3 ± 8.8410.0 ± 0.00
TNF-α: Cycle 1 Week 1 (N=31, 13, 5)87.3 ± 24160.2 ± 127285 ± 306
TNF-α: Cycle 2 Week 1 (N=4, 14, 5)10.0 ± 0.0010.0 ± 0.0010.0 ± 0.00
IL-4: Cycle 1 Week 1 (N=0, 0, 0)NA ± NANA ± NANA ± NA
IL-4: Cycle 2 Week 1 (N=0, 0, 0)NA ± NANA ± NANA ± NA

Adverse events

Collected over From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle, median treatment duration was 28 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Blinatumomab 5 µg/m²/Day—4/5 (80%)5/5 (100%)
Phase 1: Blinatumomab 15 µg/m²/Day—4/7 (57.1%)7/7 (100%)
Phase 1+2: Blinatumomab 5/15 µg/m²/Day—39/70 (55.7%)70/70 (100%)
Phase 1: Blinatumomab 15/30 µg/m²/Day—4/6 (66.7%)6/6 (100%)
Phase 1: Blinatumomab 30 µg/m²/Day—3/5 (60%)5/5 (100%)
Total—54/93 (58.1%)93/93 (100%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventPhase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1+2: Blinatumomab 5/15 µg/m²/DayPhase 1: Blinatumomab 15/30 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/DayTotal
PyrexiaGeneral disorders2/51/78/700/60/511/93
Cytokine release syndromeImmune system disorders0/51/74/700/62/57/93
Respiratory failureRespiratory, thoracic and mediastinal disorders0/52/72/701/61/56/93
Histiocytosis haematophagicBlood and lymphatic system disorders0/50/71/700/61/52/93
Cardiac failureCardiac disorders0/50/70/700/61/51/93
ColitisGastrointestinal disorders1/50/71/700/60/52/93
Gastroenteritis viralInfections and infestations1/50/70/700/60/51/93
OverdoseInjury, poisoning and procedural complications1/50/73/700/60/54/93
Tumour lysis syndromeMetabolism and nutrition disorders0/50/70/700/61/51/93
ConvulsionNervous system disorders1/50/72/700/60/53/93
Most frequent other events
Showing 10 of 189
Most frequent other events
EventPhase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1+2: Blinatumomab 5/15 µg/m²/DayPhase 1: Blinatumomab 15/30 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/DayTotal
PyrexiaGeneral disorders4/57/754/704/65/574/93
HeadacheNervous system disorders5/54/720/700/62/531/93
AnaemiaBlood and lymphatic system disorders3/52/729/702/64/540/93
HypertensionVascular disorders0/55/718/702/61/526/93
Abdominal painGastrointestinal disorders3/53/713/700/61/520/93
Blood bilirubin increasedInvestigations0/51/74/701/63/59/93
Pain in extremityMusculoskeletal and connective tissue disorders3/52/78/702/62/517/93
Blood immunoglobulin G decreasedInvestigations0/54/71/700/60/55/93
HypokalaemiaMetabolism and nutrition disorders0/54/715/703/60/522/93
PainGeneral disorders1/52/76/703/60/512/93

Baseline characteristics

Age, Customized
Age, Customized(participants)Phase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/DayPhase 1: Blinatumomab 15/30 µg/m²/DayPhase 1: Blinatumomab 5/15 µg/m²/DayPhase 2: Blinatumomab 5/15 µg/m²/DayTotal
< 2 years00008210
2 - 6 years352491134
7 - 17 years223293149
Gender
Gender(Participants)Phase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/DayPhase 1: Blinatumomab 15/30 µg/m²/DayPhase 1: Blinatumomab 5/15 µg/m²/DayPhase 2: Blinatumomab 5/15 µg/m²/DayTotal
Female3421111233
Male2335153260
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Phase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/DayPhase 1: Blinatumomab 15/30 µg/m²/DayPhase 1: Blinatumomab 5/15 µg/m²/DayPhase 2: Blinatumomab 5/15 µg/m²/DayTotal
White5755223377
Asian0000000
Black or African American0000000
American Indian or Alaska native0000000
Native Hawaiian or other Pacific islander0000000
Other0001359
Unknown0000167
Prior Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Prior Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)(participants)Phase 1: Blinatumomab 5 µg/m²/DayPhase 1: Blinatumomab 15 µg/m²/DayPhase 1: Blinatumomab 30 µg/m²/DayPhase 1: Blinatumomab 15/30 µg/m²/DayPhase 1: Blinatumomab 5/15 µg/m²/DayPhase 2: Blinatumomab 5/15 µg/m²/DayTotal
Yes3624152555
No2132111938
08

Study locations

30 sites
  • Children's Hospital Denver
    Aurora, Colorado 80045, United States
  • Children's Healthcare of Atlanta at Egleston
    Atlanta, Georgia 30322, United States
  • Washington University
    ST. Louis, Missouri, United States
  • Memorial Sloan Kettering
    New York, New York 10065, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • St Jude Children's Research Hospital
    Memphis, Tennessee 38105-3678, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390-9063, United States
  • Texas Children's Cancer Center/ Baylor
    Houston, Texas 77030-2399, United States
  • Primary Children's Medical Center
    Salt Lake City, Utah, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • St. Anna Kinderspital
    Vienna, 1090, Austria
  • Hospital for Sick Children
    Toronto, Ontario M5G1X8, Canada
  • (CHU Besancon) Hopital Saint-Jaques
    Besancon, 25030, France
  • Hôpital de la Timone (Enfants)
    Marseille, France
  • Hopital Robert Debré (AP-HP)
    Paris Cedex 19, 75935, France
  • Charité Campus Virchow Klinikum, Otto-Heubner-Centrum (OHC) für Kinder- und Jugendmedizin
    Berlin, 13353, Germany
  • Universitätsklinikum Düsseldorf
    Düsseldorf, 40225, Germany
  • Universitätsklinikum Essen
    Essen, Germany
  • Klinikum der Johann Wolfgang Goethe-Universität Frankfurt/Main
    Frankfurt am Main, 60590, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, Germany
  • Medizinische Hochschule Hannover
    Hannover, Germany
  • Universitätsklinikum Schleswig-Holstein Campus Kiel
    Kiel, Germany
  • Klinikum der Universität München, Dr. von Haunersches Kinderspital
    München, 80337, Germany
  • Universitätsklinik für Kinder- und Jugendmedizin Tübingen
    Tübingen, 72076, Germany
  • Universitätsklinikum Würzburg
    Würzburg, Germany
  • University of Milano-Bicocca, Hospital San Gerardo
    Monza, 20052, Italy
  • Dipartimento della Donna e del Bambino
    Padova, Italy
  • The Bambino Gesù Children's Hospital
    Rome, 00165, Italy
  • Erasmus MC, Sophia Children's Hospital
    Rotterdam, 3015 GJ, Netherlands
09

References and documents

Publications

  • von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016 Dec 20;34(36):4381-4389. doi: 10.1200/JCO.2016.67.3301. Epub 2016 Oct 31. PubMed 27998223 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Aug 2014 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 2 years 6 months after primary completion. A results delay was requested in Jul 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2011
First posted
Nov 16, 2011
Start
Jan 2012
Primary completionActual
Aug 2014
CompletionActual
May 2016
Results delay requested
Jul 23, 2015
Results first posted
Feb 8, 2017
Last update
Feb 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01471782
Responsible party
Sponsor
First posted
Nov 16, 2011
Start date
Jan 2012
Primary completion
Aug 2014
Completion
May 2016
Results posted
Feb 8, 2017
Last update
Feb 8, 2017

Study contacts

Arend von Stackelberg, MD
study chair · Charite University, Berlin, Germany
Lia Gore, MD
study chair · Children's Hospital Denver, USA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion